Tokyo, April 20 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061311) titled 'Rethinking B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in hemodialysis patients' on April 19.
Study Type:
Observational
Primary Sponsor:
Institute - Fujita Memorial Hospital
Condition:
Condition - 168 patients undergoing maintenance hemodialysis, 75 had not received sacubitril/valsartan, while 93 had been receiving the same medication for at least 3 months.
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Correlation between BNP and NT-proBNP according to the presence or absence of sacubitril/valsartan therapy, and changes in BNP and NT-proBNP before and after hemodialysis.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
Gender - Male and Female
Key inclusion criteria - A patient undergoing maintenance hemodialysis three times a week at Fujita Memorial Hospital.
Key exclusion criteria - Patients who have been taking sacubitril/valsartan for less than 3 months.
Target Size - 168
Recruitment Status:
Recruitment status - Completed
Date of protocol fixation - 2025 Year 07 Month 15 Day
Date of IRB - 2025 Year 04 Month 01 Day
Anticipated trial start date - 2025 Year 08 Month 01 Day
Last follow-up date - 2026 Year 03 Month 10 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070155
Disclaimer: Curated by HT Syndication.
